Bristol-Myers' Opdivo drives another top-line beat in Q3, but lung-cancer combo data looms

26th October 2017 Uncategorised 0

As Bristol-Myers Squibb’s chief commercial officer, Murdo Gordon, acknowledged on Thursday’s third-quarter conference call, “there were questions” about whether Opdivo would grow this year in the U.S. But with the drug’s third straight sales beat of the year in the books, the company has laid those questions to rest.

More: Bristol-Myers' Opdivo drives another top-line beat in Q3, but lung-cancer combo data looms
Source: fierce